CD274 and non-small cell lung carcinoma: Complicating the landscape, pembrolizumab combined with chemotherapy (i.e., chemoimmunotherapy) has demonstrated superior outcomes irrespective of PD-L1 expression in both squamous and non-squamous NSCLC populations [4,5].